Panel Discussion – Selecting Combination Partners Rationally

Time: 11:30 am
day: Day One


  • What types of features should we look for in a potential combination partner for CD73/CD39 inhibitors?
  • What can we identify as being a good partner for A2AR and A2B?
  • Discuss a methodology that can be used as a process for assessing potential combination partners that improves patient responses and safety profiles
  • Postulate what partners have not been tested and suggest reasons why these combinations could hold promise